News & Updates

Renal relapse in childhood-onset lupus nephritis: When? Who’s at risk?

06 Oct 2023 by

A 20-year retrospective study in Hong Kong has shown that renal relapse generally occurs within the first 5 years after diagnosis of childhood-onset lupus nephritis (cLN) in Chinese patients. The risk of renal relapse is higher in those diagnosed at young age, those failing to achieve complete remission (CR) 12 months after induction therapy, and those receiving maintenance therapy other than mycophenolate mofetil (MMF).

Renal relapse in childhood-onset lupus nephritis: When? Who’s at risk?

06 Oct 2023

Microscopic colitis a risk factor for rheumatoid arthritis

04 Oct 2023

Individuals with microscopic colitis have a twofold greater risk of rheumatoid arthritis (RA) compared with those in the general population, as reported in a study.

Microscopic colitis a risk factor for rheumatoid arthritis

04 Oct 2023

Otilimab for RA disappoints in ContRAst 3

25 Sep 2023

In the treatment of select patients with rheumatoid arthritis (RA), otilimab is neither better than placebo nor noninferior to sarilumab in terms of the proportion of patients achieving an American College of Rheumatology ≥20 percent response (ACR20), according to the results of the phase III ContRAst 3 study.

Otilimab for RA disappoints in ContRAst 3

25 Sep 2023

SLE rash treatment better with GC plus hydroxychloroquine combo vs GC monotherapy

16 Sep 2023

Combination treatment with glucocorticoid (GC) plus hydroxychloroquine appears to yield more favourable outcomes than GC alone in the treatment of systemic lupus erythematosus (SLE) rash, while having a good safety profile, according to a study.

SLE rash treatment better with GC plus hydroxychloroquine combo vs GC monotherapy

16 Sep 2023

Which factors predict sustained RA remission with MTX or ETN monotherapy?

12 Sep 2023 by

Following the switch from combination therapy to monotherapy, rheumatoid arthritis (RA) patients with overall lower disease activity (LDA) have higher odds of achieving and remaining in Simplified Disease Activity Index (SDAI) remission/LDA, suggests a study.

Which factors predict sustained RA remission with MTX or ETN monotherapy?

12 Sep 2023

Renal histopathology predicts kidney failure, death in patients with lupus nephritis

11 Sep 2023

Histologic variables of renal biopsy in lupus nephritis (LN) are significantly associated with kidney failure and mortality, suggests a recent study.

Renal histopathology predicts kidney failure, death in patients with lupus nephritis

11 Sep 2023

Long-term golimumab helps prevent infections in RA

10 Sep 2023

Long-term treatment with golimumab results in relatively low infection rates among patients with rheumatoid arthritis (RA), a study has shown.

Long-term golimumab helps prevent infections in RA

10 Sep 2023

Original New Drug Application Approvals by US FDA (16-31 August 2023)

01 Sep 2023

New drug applications approved by US FDA as of 16-31 August 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.